BioPharm Business News and Perspectives

Thursday, September 17, 2009 Lilly's Cymbalta Maintains Low Back Pain Relief
Data reported at a European pain meeting show that Cymbalta^® (duloxetine) maintains relief of low back pain for 41 weeks...

Thursday, September 10, 2009 Lodotra Delayed-Release Prednisone Aces Phase III
Nitec Pharma's Lodotra™ delayed-release prednisone met phase III efficacy endpoints. Nitec expects to file for FDA approval in RA...

Tuesday, September 08, 2009 RA Drug Array ARRY-162 Fails in Phase 2
A new rheumatoid drug from Array BioPharma that modulates the MEK pathway did not meet Phase 2 efficacy goals...

Thursday, August 27, 2009 Lexicon Moves LX2931 Into RA Phase 2
Lexicon's LX2931 S1P lyase blocker is in Phase 2 trials in rheumatoid arthritis...

Thursday, August 20, 2009 Animal Rights Thugs Target Novartis CEO
Animal rights extremists desecrated the graves of pharma exec Daniel Vasella's mother and sister and are now suspected of an arson attack on his house...

Tuesday, August 04, 2009 FDA Spikes Pegloticase Gout OK
Savient Pharmaceuticals' shares tanked on the FDA's refusal to approve Krystexxa™ for gout...

Thursday, July 30, 2009 GSK Buys $120 Million Piece of Denosumab
GlaxoSmithKline will share denosumab osteoporosis sales in Europe and emerging markets...

Tuesday, July 21, 2009 Belimumab Meets Lupus Phase 3 Endpoint
Benlysta^® (belimumab, formerly LymphoStat-B) was significantly better that standard care in the phase 3 BLISS-52 trial...

Thursday, July 16, 2009 Array BioPharma Stops Work on ARRY-797 Pan-Cytokine Inhibitor for RA Despite Good Early Data
The pan-cytokine inhibitor ARRY-797 was safe at doses of up to 1,200 mg/day in a phase 1 dose-escalation study in RA patients, but will not be developed further for use in RA...

Thursday, July 09, 2009 Amgen's Denosumab Bests Zometa in Breast Cancer Patients
The first of three pivotal oncology trials comparing denosumab to Zometa in the advanced cancer setting meets primary and secondary endpoints...